- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Alternative Capital and Credit Funds
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology and Emerging Companies
- Government Matters
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Insurance Coverage and Recovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries
- Careers
- News & Insights
- About
- Languages
D. Kyle Sampson
News 1 results
Press Release
April 1, 2016
King & Spalding Boosts FDA & Life Sciences Practice with Addition of Three-Lawyer Team in Washington, D.C.
Events 10 results
Webinar
November 21, 2019
FDA’s Regulation of Cannabis: What You Should Know
Conference
November 12, 2019
12th Annual King & Spalding Pharmaceutical University
Webinar
September 12, 2019
Open Borders for Rx Drugs? The Trump Administration’s Move to Authorize Prescription Drug Importation
Conference
November 13, 2018
11th Annual King & Spalding Pharmaceutical University
Insights 11 results
Client Alert
October 31, 2019
USDA Issues Interim Final Rule to Establish Domestic Hemp Production Program and Approve State and Tribal Oversight Plans
Client Alert
August 6, 2019
A Gimmick No More? HHS Moves to Authorize Prescription Drug Importation
Article · Source: Intellectual Property & Technology Law Journal
July 1, 2019
FDA Proposes Regulatory Framework for Artificial Intelligence/Machine Learning Software as a Medical Device
Client Alert
April 9, 2019
FDA Proposes Regulatory Framework for Artificial Intelligence/Machine Learning Software as a Medical Device